About Biocon Our Business Research & Development Biocon's Technology Investors Media Careers CSR
  Fact Sheet
  Vision Mission Values
  CSR Policy
  EHS Policy
  Biocon Malaysia
  Fact Sheet

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.

Biocon Biologics, a subsidiary of Biocon Ltd, is uniquely positioned as a fully integrated 'pure play' biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. It has a platform of 28 biosimilar molecules across diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases. The Company has five of its biosimilars commercialized in the developed markets like U.S., EU, Canada, Japan and Australia. It aspires to benefit 5 million patient lives with its biosimilars and attain a revenue milestone of USD 1 billion in FY22.

A Credible Biopharma Enterprise:

  • 7 Biologics taken from 'Lab to Market': 2 Novels & 5 Biosimilars
  • ~120 Countries where our Products are Available
  • 25+ cGMP Approvals from International Regulatory Agencies
  • Ranked among Top 10 Global Biotech Employers by Science magazine
  • Key Brands: INSUGEN® (rh-insulin), Basalog One® (prefilled Glargine pen), CANMAb™ (Trastuzumab), KRABEVA® (Bevacizumab), BIOMAb-EGFR® (Nimotuzumab) and ALZUMAb™ (Itolizumab)

Biocon at a Glance

Biocon is leveraging its affordable innovation model to reduce disparities in access to safe, high-quality medicines, as well as, address the gaps in scientific research to find innovative solutions to impact a billion lives.

Generics Business: Ensuring access through quality, affordability, reliability

Biosimilars Business: Expanding access through innovative, inclusive healthcare solutions

Research Services Business: Partnering to deliver innovative scientific solutions

Novel Biologics Business: Pushing scientific boundaries to deliver impactful innovations

Branded Formulations Business: Offering patients high quality, differentiated therapies

Growth Verticals:
Aligned with Shifting Paradigms


Biocon Fact Sheet


Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved